Is KRYS or LIMN more undervalued in 2026?

CirclFi compares Krystal Biotech, Inc. (KRYS) and Liminatus Pharma, Inc. (LIMN) using 13 institutional-grade valuation models. KRYS has a Quality of Company score of 7.7/10 while LIMN scores 3.5/10.

Which is a better buy — KRYS or LIMN?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do KRYS and LIMN valuations compare?

KRYS at $309.03 and LIMN at $0.16 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

KRYS vs LIMN Valuation Comparison 2026 — Intrinsic Value Analysis

KRYS

Biological Products, (No Diagnostic Substances)

Krystal Biotech, Inc.

Quality

7.7

out of 10

Value Trap

SAFE

Price

$309.03

Last close

Models

13/13

Active

LIMN

Biological Products, (No Diagnostic Substances)

Liminatus Pharma, Inc.

Quality

3.5

out of 10

Value Trap

—

Price

$0.16

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	KRYS Fair Value	KRYS Upside	LIMN Fair Value	LIMN Upside
Bayesian DCF	Intrinsic	$137.31	-55.6%	$0.09	-45.0%
Earnings Power Value	Intrinsic	$61.44	-80.1%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$30.01	-90.3%	$0.02	-85.8%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for KRYS vs LIMN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KRYS vs LIMN — Which Stock Is More Undervalued?

KRYS scores higher with a 7.7/10 quality rating vs LIMN's 3.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Krystal Biotech, Inc. (KRYS) and Liminatus Pharma, Inc. (LIMN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KRYS currently trades at $309.03 with a QOC of 7.7/10, while LIMN trades at $0.16 with a QOC of 3.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).